Ad-hoc | 28 May 2002 07:34
Eckert & Ziegler AG
english
Eckert & Ziegler: Double-Digit Growth in First Quarter
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Berlin, 28 May 2002. Eckert & Ziegler AG of Berlin, a specialist for medical and
industrial isotope applications, grew in the double digits in the first fiscal
quarter 2002. Sales increased 13% to EUR 8.1 million (prior year: EUR 7.2
million), while earnings before taxes and share of loss from its involvement in
the Immunology division (NEMOD AG) climbed 33% to EUR 1.1 million (prior year:
EUR 0.8 million). The Cardiology division posted the biggest percentage increase
in revenues surging 118% to EUR 0.9 million (prior year: EUR 0.4 million).
Above-average growth was also recorded by Nuclear Imaging with 15% to EUR 2.9
million (prior year: EUR 2.5 million) and Oncology with 21% to EUR 1.6 million
(prior year: EUR 1.3 million). Industrial Sources improved by 2% to EUR 2.6
million (prior year: EUR 2.5 million).
The Neuer Markt offers very few precedents for reporting the atypical silent
participation in NEMOD AG according to US-GAAP. For this reason, and in the
interest of prudence, KPMG as auditor chose a very conservative accounting of
the NEMOD holdings. In it, the expenses (TEUR 731) for the first quarter
reported in the Eckert & Ziegler AG income statement clearly exceeded what was
actually paid to (TEUR 600) or consumed by (TEUR 540) NEMOD. These reported
expenses result in earnings per share of 3 euro cents (or earnings of 19 euro
cents per share before deducting expenses for NEMOD). According to the auditor,
these accounting methods may change in the course of the year since new US-GAAP
rules on this issue are currently being prepared.
The Board of Directors
For further information please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D – 13125 Berlin, http://www.ezag.com
Tel.: +49 (0) 30 / 94 10 84-138, Fax: -112
end of ad-hoc-announcement (c)DGAP 28.05.2002
——————————————————————————–
WKN: 565970; ISIN: DE0005659700; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
280734 Mai 02